AP512A - Derivatives of 1-aminocarbonylmethyl-3-amino-2,4-dioxo-1-5 benzodiazepines having CCKA agonist activity. - Google Patents

Derivatives of 1-aminocarbonylmethyl-3-amino-2,4-dioxo-1-5 benzodiazepines having CCKA agonist activity. Download PDF

Info

Publication number
AP512A
AP512A APAP/P/1994/000635A AP9400635A AP512A AP 512 A AP512 A AP 512A AP 9400635 A AP9400635 A AP 9400635A AP 512 A AP512 A AP 512A
Authority
AP
ARIPO
Prior art keywords
formula
phenyl
group
compound
4alkyl
Prior art date
Application number
APAP/P/1994/000635A
Other languages
English (en)
Other versions
AP9400635A0 (en
Inventor
Elizabeth Ellen Sugg
Christopher Joseph Aquino
Jerzy Rysard Szewczyk
Harry Finch
Original Assignee
Glaxo Wellcome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc
Publication of AP9400635A0 publication Critical patent/AP9400635A0/xx
Application granted granted Critical
Publication of AP512A publication Critical patent/AP512A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0821Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0827Tripeptides containing heteroatoms different from O, S, or N
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
APAP/P/1994/000635A 1993-04-15 1994-04-13 Derivatives of 1-aminocarbonylmethyl-3-amino-2,4-dioxo-1-5 benzodiazepines having CCKA agonist activity. AP512A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939307833A GB9307833D0 (en) 1993-04-15 1993-04-15 Modulators of cholecystokinin and gastrin

Publications (2)

Publication Number Publication Date
AP9400635A0 AP9400635A0 (en) 1994-04-30
AP512A true AP512A (en) 1996-07-29

Family

ID=10733915

Family Applications (2)

Application Number Title Priority Date Filing Date
APAP/P/1994/000635A AP512A (en) 1993-04-15 1994-04-13 Derivatives of 1-aminocarbonylmethyl-3-amino-2,4-dioxo-1-5 benzodiazepines having CCKA agonist activity.
APAP/P/1994/000634A AP462A (en) 1993-04-15 1994-04-13 1,5 Benzodiazepine derivatives.

Family Applications After (1)

Application Number Title Priority Date Filing Date
APAP/P/1994/000634A AP462A (en) 1993-04-15 1994-04-13 1,5 Benzodiazepine derivatives.

Country Status (34)

Country Link
US (2) US5646140A (sk)
EP (1) EP0694039B1 (sk)
JP (1) JP3406317B2 (sk)
KR (1) KR100364948B1 (sk)
CN (1) CN1058487C (sk)
AP (2) AP512A (sk)
AT (1) ATE198894T1 (sk)
AU (1) AU681139B2 (sk)
CA (1) CA2158973C (sk)
CZ (1) CZ286695B6 (sk)
DE (1) DE69426624T2 (sk)
DK (1) DK0694039T3 (sk)
EC (1) ECSP941066A (sk)
ES (1) ES2154674T3 (sk)
FI (1) FI954853A0 (sk)
GB (1) GB9307833D0 (sk)
GR (1) GR3035641T3 (sk)
HK (1) HK1003943A1 (sk)
HU (1) HU223467B1 (sk)
IL (2) IL109315A0 (sk)
IS (2) IS4147A (sk)
MY (2) MY112237A (sk)
NO (1) NO311133B1 (sk)
NZ (1) NZ265272A (sk)
OA (1) OA10355A (sk)
PE (2) PE50994A1 (sk)
PH (1) PH30897A (sk)
PL (1) PL178790B1 (sk)
PT (1) PT694039E (sk)
RU (1) RU2135486C1 (sk)
SK (1) SK281211B6 (sk)
TW (1) TW487703B (sk)
WO (1) WO1994024149A1 (sk)
ZA (2) ZA942571B (sk)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2177960A1 (en) * 1993-12-28 1995-07-06 Sanji Hagishita Novel benzodiazepine derivative
US5739129A (en) * 1994-04-14 1998-04-14 Glaxo Wellcome Inc. CCK or gastrin modulating 5-heterocyclic-1, 5 benzodiazepines
HUT76135A (en) * 1994-04-14 1997-06-30 Glaxo Wellcome Inc Cholecystokinin and gastrin modulating 5-heterocyclic-1,5-benzodiazepines
AU2446295A (en) * 1994-04-15 1995-11-10 Glaxo Inc. A method of inducing cholecystokinin agonist activity using 1,4-benzodiazepine compounds
PE27497A1 (es) * 1994-04-15 1997-08-07 Glaxo Inc Derivados de 1,5 benzodiazepina
US5910495A (en) * 1994-10-14 1999-06-08 Glaxo Wellcome Inc. Use of 1,5-benzo b!1,4-diazepines to control gastric emptying
US5780464A (en) * 1994-10-14 1998-07-14 Glaxo Wellcome Inc. Enteric coated compositions of 1,5-benzodiazepine derivatives having CCK antagonistic or agonistic activity
GB9420747D0 (en) * 1994-10-14 1994-11-30 Glaxo Inc 1,5 benzodiazepine derivatives
GB9420763D0 (en) * 1994-10-14 1994-11-30 Glaxo Inc Acetamide derivatives
GB9420748D0 (en) * 1994-10-14 1994-11-30 Glaxo Inc 1,5 benzodiazepine derivatives
IL124808A0 (en) 1995-12-11 1999-01-26 New England Medical Center Inc Assay for and uses of peptide hormone receptor ligands
US5750353A (en) * 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
US6239131B1 (en) * 1996-12-10 2001-05-29 Zeria Pharmaceutical Co., Ltd. 1,5 Benzodiazepine derivatives
ATE344046T1 (de) 1997-04-15 2006-11-15 Csir Pflanzenextrakte mit appetitunterdrückender aktivität
AR022044A1 (es) * 1999-05-06 2002-09-04 Glaxo Group Ltd Derivados de 1,5-benzodiazepina
GB2396815B (en) 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
US6768024B1 (en) 2000-08-04 2004-07-27 Lion Bioscience Ag Triamine derivative melanocortin receptor ligands and methods of using same
US20020180095A1 (en) * 2001-05-29 2002-12-05 Berard Steven O. Thermally conductive carbon fiber extrusion compounder and method of using same
ES2319886T3 (es) * 2002-02-20 2009-05-14 Abbott Laboratories Compuestos azabiciclicos condensados que inhiben el sutipo 1 del receptor valinoide (vr1).
US7074805B2 (en) * 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US6933311B2 (en) * 2003-02-11 2005-08-23 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7015233B2 (en) 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
EP1753766A1 (en) * 2004-05-25 2007-02-21 Pfizer Products Inc. Tetraazabenzo(e)azulene derivatives and analogs thereof
CN1333077C (zh) * 2005-04-15 2007-08-22 华南农业大学 缩胆囊素活性片段的串联表达及其应用
JP2010501592A (ja) * 2006-08-25 2010-01-21 アボット・ラボラトリーズ Trpv1を阻害するインダゾール誘導体およびその使用
EP2134678A2 (en) 2006-12-20 2009-12-23 Abbott Laboratories N-(5, 6, 7, 8-tetrahydronaphthalen-1-yl) urea derivatives and related compounds as trpv1 vanilloid receptor antagonists for the treatment of pain
EP2489660A1 (en) * 2008-03-20 2012-08-22 Abbott Laboratories Methods for making central nervous system agents that are TRPV1 antagonists
CN103102285B (zh) * 2013-01-30 2015-07-29 淮阴师范学院 对氨基苯乙腈的制备方法
CN106029076B (zh) 2013-11-18 2019-06-07 福马疗法公司 作为bet溴域抑制剂的苯并哌嗪组合物
TWI742513B (zh) 2013-11-18 2021-10-11 美商弗瑪治療公司 作為bet溴域抑制劑之四氫喹啉組成物
HUE060259T2 (hu) 2015-07-22 2023-02-28 Enanta Pharm Inc Benzodiazepin származékok mint RSV-gátlók
JP6974331B2 (ja) 2016-02-05 2021-12-01 デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. 化合物、組成物及び方法
HUE058802T2 (hu) 2016-12-09 2022-09-28 Denali Therapeutics Inc RIPK1 inhibitorokként alkalmas vegyületek
CA3065368A1 (en) 2017-02-16 2018-08-23 Enanta Pharmaceuticals, Inc. Processes for the preparation of benzodiazepine derivatives
US10752598B2 (en) * 2017-06-07 2020-08-25 Enanta Pharmaceuticals, Inc. Aryldiazepine derivatives as RSV inhibitors
US11091501B2 (en) 2017-06-30 2021-08-17 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
US10851115B2 (en) 2017-06-30 2020-12-01 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
BR112020006334A2 (pt) 2017-09-29 2020-09-24 Enanta Pharmaceuticals, Inc. combinação de agentes farmacêuticos como inibidores de rsv
WO2019094920A1 (en) 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Azepin-2-one derivatives as rsv inhibitors
US10975094B2 (en) 2018-04-11 2021-04-13 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
KR20210138684A (ko) 2019-03-18 2021-11-19 이난타 파마슈티칼스, 인코포레이티드 Rsv 억제제로서의 벤조디아제핀 유도체
US11179400B2 (en) 2019-04-09 2021-11-23 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
US11534439B2 (en) 2020-07-07 2022-12-27 Enanta Pharmaceuticals, Inc. Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors
WO2022086840A1 (en) 2020-10-19 2022-04-28 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
AU2023206890A1 (en) 2022-01-12 2024-08-22 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0376849A1 (fr) * 1988-12-29 1990-07-04 Roussel-Uclaf Nouveaux dérivés de la 2,4-dioxo 2,3,4,5-tétrahydro 1H-1,5-benzodiazépine, leur procédé et les intermédiaires de préparation, leur application comme médicaments et les compositions les renfermant
WO1993014074A1 (en) * 1992-01-21 1993-07-22 Glaxo Spa 1,5-benzodiazepine derivatives and their use in medicine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2659653B1 (fr) * 1990-03-13 1992-05-22 Rhone Poulenc Sante Derives de l'uree, leur preparation et les medicaments les contenant.
US5206234A (en) * 1990-10-22 1993-04-27 Merck & Co., Inc. Benzolactam analogs as antagonists of cck
JP2904941B2 (ja) * 1991-01-28 1999-06-14 出光興産株式会社 スチレン系重合体の精製方法
HUT76135A (en) * 1994-04-14 1997-06-30 Glaxo Wellcome Inc Cholecystokinin and gastrin modulating 5-heterocyclic-1,5-benzodiazepines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0376849A1 (fr) * 1988-12-29 1990-07-04 Roussel-Uclaf Nouveaux dérivés de la 2,4-dioxo 2,3,4,5-tétrahydro 1H-1,5-benzodiazépine, leur procédé et les intermédiaires de préparation, leur application comme médicaments et les compositions les renfermant
WO1993014074A1 (en) * 1992-01-21 1993-07-22 Glaxo Spa 1,5-benzodiazepine derivatives and their use in medicine

Also Published As

Publication number Publication date
GB9307833D0 (en) 1993-06-02
CA2158973A1 (en) 1994-10-27
NZ265272A (en) 1997-07-27
IL109316A0 (en) 1994-07-31
GR3035641T3 (en) 2001-06-29
IS4147A (is) 1994-10-16
MY112237A (en) 2001-05-31
HK1003943A1 (en) 1998-11-13
AU681139B2 (en) 1997-08-21
JPH08508744A (ja) 1996-09-17
PL311084A1 (en) 1996-02-05
ZA942571B (en) 1994-11-11
IL109316A (en) 1999-03-12
HU223467B1 (hu) 2004-07-28
IS4148A (is) 1994-10-16
FI954853A (fi) 1995-10-12
HUT74102A (en) 1996-11-28
RU2135486C1 (ru) 1999-08-27
PE50994A1 (es) 1995-01-06
HU9502978D0 (en) 1995-12-28
AP9400634A0 (en) 1994-04-30
PE50594A1 (es) 1995-01-06
AP462A (en) 1996-02-19
DK0694039T3 (da) 2001-05-21
FI954853A0 (fi) 1995-10-12
US5646140A (en) 1997-07-08
PL178790B1 (pl) 2000-06-30
US5585376A (en) 1996-12-17
CN1058487C (zh) 2000-11-15
JP3406317B2 (ja) 2003-05-12
NO954090D0 (no) 1995-10-13
OA10355A (en) 2001-10-19
SK281211B6 (sk) 2001-01-18
AU6567694A (en) 1994-11-08
CZ267595A3 (en) 1996-04-17
ZA942570B (en) 1994-11-11
CZ286695B6 (en) 2000-06-14
EP0694039A1 (en) 1996-01-31
SK125395A3 (en) 1996-06-05
TW487703B (en) 2002-05-21
MY131569A (en) 2007-08-30
PT694039E (pt) 2001-06-29
CN1120843A (zh) 1996-04-17
NO954090L (no) 1995-12-13
NO311133B1 (no) 2001-10-15
CA2158973C (en) 2006-06-06
ES2154674T3 (es) 2001-04-16
AP9400635A0 (en) 1994-04-30
PH30897A (en) 1997-12-23
WO1994024149A1 (en) 1994-10-27
IL109315A0 (en) 1994-07-31
DE69426624T2 (de) 2001-06-21
EP0694039B1 (en) 2001-01-24
KR100364948B1 (ko) 2003-03-29
ECSP941066A (es) 1994-11-16
DE69426624D1 (de) 2001-03-01
ATE198894T1 (de) 2001-02-15

Similar Documents

Publication Publication Date Title
AP512A (en) Derivatives of 1-aminocarbonylmethyl-3-amino-2,4-dioxo-1-5 benzodiazepines having CCKA agonist activity.
US5795887A (en) Method of inducing cholecystokinin agonist activity using 1,4- Benzodiazepine compounds
AU679085B2 (en) Benzodiazepine analogs
US5739129A (en) CCK or gastrin modulating 5-heterocyclic-1, 5 benzodiazepines
EP0756602B1 (en) Cck or gastrin modulating 5-heterocyclic-1,5-benzodiazepines
CA2158972A1 (en) 1,5-benzodiazepine derivatives having cck and/or gastrin antogonistic activity
US5910495A (en) Use of 1,5-benzo b!1,4-diazepines to control gastric emptying